Area of research
Infectious Diseases · Animal Science and Zoology
Research interest
Research interests include SARS-CoV-2 and COVID-19 Research, COVID-19 Clinical Research Studies, SARS-CoV-2 detection and testing, and Viral gastroenteritis research and epidemiology.
From nicotine to SARS-CoV-2 antivirals with potent in vivo efficacy and a broad anti-coronavirus spectrum.
TRIM7 ubiquitinates SARS-CoV-2 membrane protein to limit apoptosis and viral replication.
Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster.
AT-752 targets multiple sites and activities on the Dengue virus replication enzyme NS5.
SARS-COV-2 Omicron variants conformationally escape a rare quaternary antibody binding mode.
Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection.
A live-attenuated SARS-CoV-2 vaccine candidate with accessory protein deletions.
Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine.
Engineering SARS-CoV-2 specific cocktail antibodies into a bispecific format improves neutralizing potency and breadth.
Antibody escape and cryptic cross-domain stabilization in the SARS-CoV-2 Omicron spike protein
Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines.
Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2.
BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variants.
Publisher Correction: A live-attenuated SARS-CoV-2 vaccine candidate with accessory protein deletions.
Spike mutation D614G alters SARS-CoV-2 fitness.
Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera.
BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants.
Inhibition of SARS-CoV-2 polymerase by nucleotide analogs from a single-molecule perspective.
A trans-complementation system for SARS-CoV-2 recapitulates authentic viral replication without virulence.
Mucosal vaccination induces protection against SARS-CoV-2 in the absence of detectable neutralizing antibodies.
Author Correction: Spike mutation D614G alters SARS-CoV-2 fitness.
Inhibition of innate immune response ameliorates Zika virus-induced neurogenesis deficit in human neural stem cells.
Neutralization of SARS-CoV-2 variants B.1.617.1 and B.1.525 by BNT162b2-elicited sera
Evasion of Type I Interferon by SARS-CoV-2.
Envelope protein ubiquitination drives entry and pathogenesis of Zika virus
Envelope protein ubiquitination drives entry and pathogenesis of Zika virus.
A Zika virus envelope mutation preceding the 2015 epidemic enhances virulence and fitness for transmission.
Role of microglia in the dissemination of Zika virus from mother to fetal brain.
A cocrystal structure of dengue capsid protein in complex of inhibitor.
Spike mutation D614G alters SARS-CoV-2 fitness and neutralization susceptibility